CDRT1

Across TCGA pan-cancer cohorts, CDRT1 Mutation is linked to patient survival in 5 of 34 cancer types, making it a survival-associated CDRT1 data layer compared with 22 for mass-spec protein.

The strongest signal is observed in liver hepatocellular carcinoma (LIHC), where higher CDRT1 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated CDRT1 expression acts as an unfavorable survival marker.

LIHC, SCLC, and ESCA are the cancer types where CDRT1 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LIHC	OS	Median	All	0.051	0.777	<.001	36	view →
SCLC	DFS	Median	All	0.164	0.625	.018	12	view →
ESCA	OS	Median	All	0.095	0.701	<.001	12	view →
PRAD	DFS	Median	All	0.085	0.774	<.001	6	view →
UCEC	OS	Median	IV	0.231	0.592	.036	6	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

CDRT1–LIHC (OS)

Open the LIHC breakdown →